What’s Next for Haemonetics Corporation (HAE) After Making All-Time High?

April 17, 2018 - By Stephen Andrade

Haemonetics Corporation (NYSE:HAE) Logo

Investors sentiment decreased to 1.11 in 2017 Q4. Its down 0.17, from 1.28 in 2017Q3. It dropped, as 20 investors sold Haemonetics Corporation shares while 77 reduced holdings. 48 funds opened positions while 60 raised stakes. 50.89 million shares or 3.15% less from 52.55 million shares in 2017Q3 were reported.
Parkside National Bank And Tru has 0% invested in Haemonetics Corporation (NYSE:HAE) for 32 shares. First Quadrant Limited Partnership Ca reported 0.01% stake. Janney Montgomery Scott Ltd Co reported 0.03% of its portfolio in Haemonetics Corporation (NYSE:HAE). American Century owns 193,013 shares or 0.01% of their US portfolio. Cubist Systematic Strategies Ltd Liability Corporation, Connecticut-based fund reported 8,961 shares. Arizona State Retirement has invested 0.05% of its portfolio in Haemonetics Corporation (NYSE:HAE). Pitcairn has invested 0.04% in Haemonetics Corporation (NYSE:HAE). Parallax Volatility Advisers Lp accumulated 8,064 shares. Qs Investors Ltd, New York-based fund reported 1,377 shares. Millennium Management Ltd accumulated 0.01% or 63,429 shares. Service Automobile Association holds 140,844 shares. Blackrock holds 6.67 million shares. Bessemer accumulated 38,000 shares or 0.01% of the stock. Dupont Cap owns 0.03% invested in Haemonetics Corporation (NYSE:HAE) for 25,457 shares. Pinebridge Investments Ltd Partnership reported 50,410 shares stake.

Since January 2, 2018, it had 0 buys, and 3 selling transactions for $484,765 activity. Scanlan Jacqueline also sold $8,234 worth of Haemonetics Corporation (NYSE:HAE) shares. KROLL MARK W sold $448,434 worth of Haemonetics Corporation (NYSE:HAE) on Tuesday, January 2.

The stock of Haemonetics Corporation (NYSE:HAE) reached all time high today, Apr, 17 and still has $77.22 target or 3.00 % above today’s $74.97 share price. This indicates more upside for the $4.01B company. This technical setup was reported by Barchart.com. If the $77.22 PT is reached, the company will be worth $120.21 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 0.29% or $0.22 during the last trading session, reaching $74.97. About 140,755 shares traded. Haemonetics Corporation (NYSE:HAE) has risen 82.56% since April 17, 2017 and is uptrending. It has outperformed by 71.01% the S&P500.

Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on May, 14. They expect $0.43 EPS, up 10.26 % or $0.04 from last year’s $0.39 per share. HAE’s profit will be $22.98M for 43.59 P/E if the $0.43 EPS becomes a reality. After $0.62 actual EPS reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts -30.65 % negative EPS growth.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 4 analysts covering Haemonetics Corp (NYSE:HAE), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Haemonetics Corp had 9 analyst reports since November 8, 2017 according to SRatingsIntel. Raymond James upgraded the stock to “Market Perform” rating in Tuesday, January 2 report. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, January 2. Morgan Stanley maintained the stock with “Buy” rating in Wednesday, March 28 report. The stock of Haemonetics Corporation (NYSE:HAE) has “Equal-Weight” rating given on Thursday, November 9 by Morgan Stanley. Craig Hallum maintained the stock with “Hold” rating in Wednesday, November 8 report. Jefferies maintained the shares of HAE in report on Wednesday, February 7 with “Buy” rating. The company was maintained on Monday, January 8 by Jefferies. Morgan Stanley maintained the shares of HAE in report on Wednesday, February 7 with “Overweight” rating. The company was maintained on Thursday, December 21 by Jefferies.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $4.01 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It currently has negative earnings. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: